A low-calorie diet paired with supervised exercise induced remission in 54% of adults with early-onset type 2 diabetes without medication, while effectively burning fat and preserving muscle mass
The Clinical Trial and 24-Week Program
A clinical trial published in The Lancet and presented at the European Association for the Study of Diabetes (EASD) meeting investigated whether early-onset type 2 diabetes could be reversed without drugs. Because younger patients typically face more aggressive complications, researchers enrolled 96 participants with obesity (aged 45 or younger, mean diabetes duration of 2.3 years, not on insulin) and divided them into usual care or an intensive lifestyle program:
-
Weeks 1–12 (Intensive Phase): An 800–900 calorie-per-day meal-replacement plan (e.g., Optifast shakes, transitioning to one solid meal per day) supervised by doctors and dieticians, combined with twice-weekly guided aerobic and resistance workouts plus one weekly independent session.
-
Weeks 13–24 (Maintenance Phase): A transition to food-based weight maintenance supported by independent regular exercise.
-
Medication Protocol: All blood glucose and blood pressure medications were discontinued at the start of the study under close clinical monitoring.
Key Clinical Results and Health Benefits
At 24 weeks, the intervention delivered substantial cardiometabolic improvements, achieving a 90% completion rate without serious adverse events:
-
High Remission Rate: 54% of participants achieved diabetes remission (HbA1c below 6.5% for at least 12 weeks off medication) compared to only 4% in usual care.
-
Targeted Fat Loss: Participants lost significant total body weight (-7.0%), overall fat mass (-16.5%), and critical fat deposits in the liver (-9.1%) and pancreas (-1.3%).
-
Preserved Muscle Health: MRI scans confirmed that lean muscle mass and muscle volume were fully maintained despite strict calorie cutting, while handgrip strength and cardiovascular fitness increased.
-
Cardiometabolic & Mental Health Gains: The program yielded lower blood pressure, reduced resting heart rate, lower triglycerides, fewer depressive symptoms, and significant drops in diabetes-related distress.
Real-World Challenges and Long-Term Value
Despite these compelling outcomes, experts highlighted critical points for implementing this approach outside a research setting:
-
Supervision and Cost: Direct exercise coaching was key to participant motivation and adherence, but providing supervised sessions in standard, resource-constrained healthcare systems is difficult and costly.
-
Durability of Results: Sustaining extreme weight loss after a low-calorie diet remains an ongoing risk for relapse.
-
Cumulative Health Benefits: Independent specialists emphasized that every year spent in remission substantially cuts the lifetime risk of cardiovascular and kidney complications, establishing structured lifestyle intervention as a potent non-drug alternative for younger adults.
A clinical trial published in The Lancet and presented at the European Association for the Study of Diabetes (EASD) meeting investigated whether early-onset type 2 diabetes could be reversed without drugs. Because younger patients typically face more aggressive complications, researchers enrolled 96 participants with obesity (aged 45 or younger, mean diabetes duration of 2.3 years, not on insulin) and divided them into usual care or an intensive lifestyle program:
-
Weeks 1–12 (Intensive Phase): An 800–900 calorie-per-day meal-replacement plan (e.g., Optifast shakes, transitioning to one solid meal per day) supervised by doctors and dieticians, combined with twice-weekly guided aerobic and resistance workouts plus one weekly independent session.
-
Weeks 13–24 (Maintenance Phase): A transition to food-based weight maintenance supported by independent regular exercise.
-
Medication Protocol: All blood glucose and blood pressure medications were discontinued at the start of the study under close clinical monitoring.
Key Clinical Results and Health Benefits
At 24 weeks, the intervention delivered substantial cardiometabolic improvements, achieving a 90% completion rate without serious adverse events:
-
High Remission Rate: 54% of participants achieved diabetes remission (HbA1c below 6.5% for at least 12 weeks off medication) compared to only 4% in usual care.
-
Targeted Fat Loss: Participants lost significant total body weight (-7.0%), overall fat mass (-16.5%), and critical fat deposits in the liver (-9.1%) and pancreas (-1.3%).
-
Preserved Muscle Health: MRI scans confirmed that lean muscle mass and muscle volume were fully maintained despite strict calorie cutting, while handgrip strength and cardiovascular fitness increased.
-
Cardiometabolic & Mental Health Gains: The program yielded lower blood pressure, reduced resting heart rate, lower triglycerides, fewer depressive symptoms, and significant drops in diabetes-related distress.
Real-World Challenges and Long-Term Value
Despite these compelling outcomes, experts highlighted critical points for implementing this approach outside a research setting:
-
Supervision and Cost: Direct exercise coaching was key to participant motivation and adherence, but providing supervised sessions in standard, resource-constrained healthcare systems is difficult and costly.
-
Durability of Results: Sustaining extreme weight loss after a low-calorie diet remains an ongoing risk for relapse.
-
Cumulative Health Benefits: Independent specialists emphasized that every year spent in remission substantially cuts the lifetime risk of cardiovascular and kidney complications, establishing structured lifestyle intervention as a potent non-drug alternative for younger adults.
Source
Medscape
